Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evolving pathophysiologic concepts in nonalcoholic steatohepatitis.

Brent A Neuschwander-Tetri1

  • 1Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, 3635 Vista Avenue, St. Louis, MO 63110, USA. tetriba@slu.edu

Current Gastroenterology Reports
|February 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The metabolic vulnerability index predicts outcomes in patients with metabolic dysfunction associated steatotic liver disease.

Nature communications·2026
Same author

Vitamin E dosing study (VEDS) in patients with metabolic dysfunction-associated steatotic liver disease with elevated aminotransferases: A multicenter, randomized, placebo-controlled trial.

Hepatology (Baltimore, Md.)·2026
Same author

Clinically distinct metabotypes of pediatric MASLD identified through unsupervised clustering of NASH CRN data.

Nature communications·2026
Same author

Longitudinal changes in cardiometabolic risk factors are associated with changes in liver stiffness in adults with MASLD.

Journal of hepatology·2026
Same author

Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Association between pattern of hepatic iron deposition and severity of MASH among patients enrolled in the NASH Clinical Research Network.

Hepatology communications·2025

Nonalcoholic steatohepatitis (NASH) affects 3% of adults and can lead to cirrhosis. Research suggests insulin resistance may drive NASH, prompting trials to test insulin resistance treatments.

Area of Science:

  • Hepatology
  • Endocrinology
  • Pathology

Background:

  • Nonalcoholic steatohepatitis (NASH) is a prevalent liver disorder affecting 3% of adults.
  • It is a subset of nonalcoholic fatty liver disease (NAFLD), characterized by excess liver fat, inflammation, and potential cell injury.
  • NASH can progress to cirrhosis in 15-40% of affected individuals.

Purpose of the Study:

  • To review the pathogenesis of NASH, focusing on the role of insulin resistance.
  • To highlight the diagnostic criteria for NASH based on liver biopsy findings.
  • To discuss the implications of emerging evidence for future therapeutic strategies.

Main Methods:

  • Review of existing literature on NASH epidemiology, risk factors, and pathogenesis.
  • Analysis of diagnostic criteria, including morphologic changes on liver biopsy.

Related Experiment Videos

  • Examination of the link between insulin resistance, hyperinsulinemia, and NASH development.

    • Main Results:

    • NASH is a significant health concern with a notable prevalence and risk of progression to cirrhosis.
    • Obesity and type 2 diabetes are key risk factors, strongly associated with insulin resistance.
    • Hyperinsulinemia, a consequence of insulin resistance, is implicated in the underlying mechanisms of NASH.

    Conclusions:

    • Insulin resistance is a critical factor in the development of NASH.
    • Further clinical trials are necessary to evaluate the efficacy of targeting insulin resistance as a NASH therapy.
    • Understanding the pathogenesis is crucial for developing effective treatments for this growing liver disease.